A Phase 4 interventional study of methotrexate (MTX) and adalimumab (ADA) in Psoriatic Arthritis, sponsored by AbbVie. Completed at 60 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing methotrexate in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 1 of them phase 3. Methotrexate · Arthritis, Psoriatic.
Among the 10 studies testing methotrexate in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 4, and was the 4th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 10 studies testing methotrexate in Arthritis, Psoriatic are open now, in 4 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–50
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 112 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Arthritis, Psoriatic by AbbVie: 4 open now, 6 under way, 3 of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2016, is the only one in phase 4, and was the 18th registered.
AbbVie’s Arthritis, Psoriatic studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing methotrexate in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 34 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in participants with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 (Day 1 up to Week 16) is designed to compare the achievement of minimal disease activity (MDA) between participants randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the highest recommended or tolerable dose; Part 2 (Week 16 through Week 32) is designed to evaluate the maintenance or achievement of MDA on 4 different treatment regimens using adalimumab and/or MTX, with participant allocation based on the initial randomized treatment and achievement of MDA in Part 1, and with rescue treatment option.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
Drug: methotrexate (MTX)
Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
Drug: methotrexate (MTX) · Biological: adalimumab (ADA)
Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
Drug: methotrexate (MTX)
Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
Drug: methotrexate (MTX) · Biological: adalimumab (ADA)
Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
Biological: adalimumab (ADA)
Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
Drug: methotrexate (MTX) · Biological: adalimumab (ADA)
Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1)
Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
Time frame: Week 16
Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1)
The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
Time frame: From Day 1 to Week 16
Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1)
Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement.
Time frame: From Day 1 to Week 16
Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1)
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement.
Time frame: From Day 1 to Week 16
Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1)
Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement.
Time frame: From Day 1 to Week 16
Percentage of Participants Achieving American College of Rheumatology (ACR) 20/50/70 Response (Part 1)
The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.
Time frame: Week 16
Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline
The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement.
Time frame: From Day 1 to Week 16
Percentage of Participants in MDA in Part 2 of the Study (Week 32)
MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
Time frame: Week 32
Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1)
Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. .
Time frame: From Day 1 to week 16
Change in Short Form Health Survey 36 (SF-36) Score From Baseline (Part 1)
The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement.
Time frame: From Day 1 to Week 16
Change in HAQ-DI Score From Baseline (Part 1)
The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement.
Time frame: From Day 1 to Week 16
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75/90/100 Response Among Participants With BSA Greater Than or Equal to 3% at Baseline (Part 1)
Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis.
Time frame: Week 16
Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1)
Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.
Time frame: From Day 1 to Week 16
There were 246 participants randomized; 1 participant did not receive study medication. Upon completion of Part 1, eligible participants continued to Part 2, so no additional participants were enrolled in Part 2.
| Milestone | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Part 2: MTX Escalated Dose | Part 2: ADA +MTX Escalated Dose | Part 2: ADA | Part 2: ADA ew + MTX |
|---|---|---|---|---|---|---|
| Started | 122 | 123 | 0 | 0 | 0 | 0 |
| Completed | 110 | 117 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal consent | 8 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Part 2: MTX Escalated Dose | Part 2: ADA +MTX Escalated Dose | Part 2: ADA | Part 2: ADA ew + MTX |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 15 | 95 | 54 | 63 |
| Completed | 0 | 0 | 15 | 91 | 52 | 57 |
| Not completed | 0 | 0 | 0 | 4 | 2 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Withdrawal consent | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 3 |
Minimal disease activity (MDA) for psoriatic arthritis (PsA) was defined as fulfilling at least 5 of the following 7 criteria: tender and swollen joint counts (TJC) ≤ 1 (out of TJC68 assessed in this study), swollen joint count (SJC) ≤ 1 (out of SJC66 assessed in this study), Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3; Patient's assessment of pain visual analogue scale (VAS) ≤ 15, Patient's global assessment of disease activity (PtGA) VAS ≤ 20, Health Assessment Questionnaire Disability Index (HAQ-DI) score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
| percentage of participants | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) | 13.1 (7.1 to 19.1) | 41.5 (32.8 to 50.2) |
The Dermatology Life Quality Index (DLQI) score is a measure of participant's quality of life (QOL) related to skin disease.The DLQI questionnaire consists of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health related QOL over the last week. The items of the DLQI encompass aspects such as symptoms and feelings, daily activities, leisure, work or school, personal relationships and the side effects of treatment. The range of possible DLQI scores is 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Dermatology Life Quality Index (DLQI) Score From Baseline (Part 1) | -3.1 (-3.85 to -2.30) | -5.9 (-6.70 to -5.20) |
Hands and feet bilaterally were assessed for the presence/absence of dactylitis and associated tenderness for participants with presence of dactylitis at baseline. The tender dactylitic digit count is equal to the number of swollen and painful digits (range 0 to 20). A decrease indicates improvement.
| count of fingers/ toes with dactylitis | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Tender Dactylitic Digit Count From Baseline for Participants With Presence of Dactylitis at Baseline (Part 1) | -0.9 (-1.48 to -0.41) | -2.8 (-3.35 to -2.23) |
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity but is also used in PsA clinical trials. DAS28 is a composite score calculated using a mathematical formula based on the scores for these scales. DAS28 includes tender and swollen joint counts, PtGA, and acute phase reactant (CRP in this study). DAS28 scores range from 0 to 10, with higher scores indicating more disease activity. A larger negative change in the DAS28 score indicates greater improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Disease Activity Score 28 (DAS28)-C-reactive Protein (CRP) Score From Baseline (Part 1) | -0.9 (-1.08 to -0.65) | -2.0 (-2.16 to -1.75) |
Psoriatic Arthritis Impact of Disease Score (PsAID) was developed by an European League Against Rheumatism (EULAR) initiative and is a validated patient self-reported tool to assess the impact of PsA on the participant's life. The PsAID is a composite score calculated using a mathematical formula based on the scores for each component. PsAID-9 was developed for clinical trials and was used in this study. The PsAID-9 is calculated based on 9 Numerical rating scales (NRS) questions that include pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, and anxiety). Each NRS is assessed as a number between 0 and 10. PsAID scores range from 0 to 10, with higher scores indicating worse status. A larger negative change in the PsAID-9 score indicates greater improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Psoriatic Arthritis Impact of Disease Score (PsAID) Score From Baseline (Part 1) | -1.7 (-2.09 to -1.28) | -3.3 (-3.73 to -2.95) |
The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20/50/70 response is achieved if ≥ 20%/≥ 50%/≥ 70% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.
| percentage of participants | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| ACR 20 | 32.8 (24.5 to 41.1) | 67.5 (59.2 to 75.8) |
| ACR 50 | 16.4 (9.8 to 23.0) | 45.5 (36.7 to 54.3) |
| ACR 70 | 8.2 (3.3 to 13.1) | 30.9 (22.7 to 39.1) |
The Leeds Enthesitis Index (LEI) is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions for participants with presence of LEI at baseline.Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for an overall score range of 0 to 6. A decrease in LEI indicates improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Leeds Enthesitis Index (LEI) From Baseline (Part 1) for Participants With Presence of LEI at Baseline | -1.1 (-1.43 to -0.75) | -1.9 (-2.22 to -1.54) |
MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1 (out of 8 assessed in this study).
| percentage of participants | Part 2: MTX Escalated Dose | Part 2: ADA + MTX Escalated Dose | Part 2: ADA | Part 2: ADA ew + MTX |
|---|---|---|---|---|
| Percentage of Participants in MDA in Part 2 of the Study (Week 32) | 66.7 (42.8 to 90.5) | 54.9 (44.7 to 65.2) | 80.4 (69.5 to 91.3) | 29.8 (17.9 to 41.7) |
Psoriatic Arthritis Disease Activity Score (PASDAS) is a weighted disease activity measure developed specifically for PsA. It includes PhGA, PtGA, SF-36 PCS, SJC, TJC, Leeds enthesitis count, tender dactylitic count and hsCRP lab test. The PASDAS is a composite score calculated using a mathematical formula based on the scores for each component. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement. .
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Psoriatic Arthritis Disease Activity Score (PASDAS) From Baseline (Part 1) | -1.2 (-1.46 to -0.86) | -2.8 (-3.05 to -2.48) |
The Short Form Health Survey 36 (SF-36) is a generic measure to assess participant's general health/well-being (health related quality of life); short version 2 (SF-36v2) was used. SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise physical component of the SF-36. Scores on each item were summed and averaged (PCS; range = 0-100). Items 5-8 comprise mental component of the SF-36. Scores on each item were summed and averaged (mental component score \[MCS\]; range = 0-100). Larger values on SF-36 indicate a better condition. A positive change from Baseline in either PCS or MCS indicates improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| SF-36 PCS | 4.4 (3.07 to 5.73) | 8.9 (7.58 to 10.15) |
| SF-36 MCS | 1.3 (-0.36 to 2.97) | 4.4 (2.85 to 6.05) |
The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline indicates improvement.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in HAQ-DI Score From Baseline (Part 1) | -0.3 (-0.39 to -0.21) | -0.5 (-0.60 to -0.42) |
Psoriasis Area and Severity Index (PASI) provides a quantitative assessment of psoriasis lesional burden based on the amount of body surface area involved and the degree of severity of erythema, induration, and scale, weighted by body part. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. 75/90/100 denotes greater than or equal to 75%/90%/100% improvement in PASI score. A 100% reduction is considered complete clearance of psoriasis.
| percentage of participants | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| PASI 75 | 31.0 (21.3 to 40.8) | 73.1 (63.2 to 82.9) |
| PASI 90 | 18.4 (10.3 to 26.5) | 57.7 (46.7 to 68.7) |
| PASI 100 | 9.2 (3.1 to 15.3) | 29.5 (19.4 to 39.6) |
Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.
| score on a scale | Part 1: MTX Escalated Dose | Part 1: ADA + MTX |
|---|---|---|
| Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline (Part 1) | -12.1 (-15.57 to -8.69) | -28.2 (-31.60 to -24.87) |
Collected over All adverse events reported from the time of study medication administration until 70 days following discontinuation of study medication administration have elapsed.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MTX Escalated Dose | 0/122 (0%) | 0/122 (0%) | 32/122 (26.2%) |
| Part 1: ADA + MTX | 0/123 (0%) | 2/123 (1.6%) | 24/123 (19.5%) |
| Part 2: MTX Escalated Dose | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Part 2: ADA + MTX Escalated Dose | 0/95 (0%) | 3/95 (3.2%) | 25/95 (26.3%) |
| Part 2: ADA | 0/54 (0%) | 1/54 (1.9%) | 5/54 (9.3%) |
| Part 2: ADA ew + MTX | 0/63 (0%) | 3/63 (4.8%) | 20/63 (31.7%) |
| Event | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Part 2: MTX Escalated Dose | Part 2: ADA + MTX Escalated Dose | Part 2: ADA | Part 2: ADA ew + MTX |
|---|---|---|---|---|---|---|
| LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications | 0/122 | 0/123 | 0/15 | 0/95 | 1/54 | 0/63 |
| URETEROLITHIASISRenal and urinary disorders | 0/122 | 0/123 | 0/15 | 0/95 | 1/54 | 0/63 |
| GASTRIC MUCOSA ERYTHEMAGastrointestinal disorders | 0/122 | 0/123 | 0/15 | 0/95 | 0/54 | 1/63 |
| GASTRITISGastrointestinal disorders | 0/122 | 0/123 | 0/15 | 0/95 | 0/54 | 1/63 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/122 | 0/123 | 0/15 | 0/95 | 0/54 | 1/63 |
| UTERINE POLYPReproductive system and breast disorders | 0/122 | 0/123 | 0/15 | 0/95 | 0/54 | 1/63 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 0/122 | 0/123 | 0/15 | 0/95 | 0/54 | 1/63 |
| DIVERTICULITISInfections and infestations | 0/122 | 0/123 | 0/15 | 1/95 | 0/54 | 0/63 |
| SUBCUTANEOUS ABSCESSInfections and infestations | 0/122 | 0/123 | 0/15 | 1/95 | 0/54 | 0/63 |
| ANKLE FRACTUREInjury, poisoning and procedural complications | 0/122 | 0/123 | 0/15 | 1/95 | 0/54 | 0/63 |
| Event | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Part 2: MTX Escalated Dose | Part 2: ADA + MTX Escalated Dose | Part 2: ADA | Part 2: ADA ew + MTX |
|---|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 11/122 | 10/123 | 0/15 | 13/95 | 2/54 | 9/63 |
| NAUSEAGastrointestinal disorders | 11/122 | 5/123 | 1/15 | 4/95 | 0/54 | 1/63 |
| HEADACHENervous system disorders | 2/122 | 10/123 | 0/15 | 0/95 | 0/54 | 0/63 |
| HEPATITISHepatobiliary disorders | 0/122 | 0/123 | 1/15 | 0/95 | 0/54 | 0/63 |
| BRONCHITISInfections and infestations | 0/122 | 0/123 | 1/15 | 1/95 | 0/54 | 0/63 |
| PNEUMONIAInfections and infestations | 0/122 | 0/123 | 1/15 | 0/95 | 0/54 | 1/63 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/122 | 0/123 | 1/15 | 2/95 | 1/54 | 3/63 |
| TRANSAMINASES INCREASEDInvestigations | 0/122 | 0/123 | 1/15 | 0/95 | 0/54 | 1/63 |
| PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders | 0/122 | 0/123 | 1/15 | 0/95 | 0/54 | 4/63 |
| DRUG INTOLERANCEGeneral disorders | 8/122 | 0/123 | 0/15 | 0/95 | 0/54 | 0/63 |
The Intent-To-Treat Part 1 (ITT Part 1) population comprises all participants who were randomized and received at least one dose of the study medication during Part 1.
| Age, Continuous(years) | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Total |
|---|---|---|---|
| Mean | 48.8 ± 12.69 | 51.4 ± 12.23 | 50.1 ± 12.50 |
| Sex: Female, Male(Participants) | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Total |
|---|---|---|---|
| Female | 59 | 64 | 123 |
| Male | 63 | 59 | 122 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 27 | 54 |
| Not Hispanic or Latino | 95 | 96 | 191 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: MTX Escalated Dose | Part 1: ADA + MTX | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 2 | 4 |
| White | 111 | 115 | 226 |
| More than one race | 2 | 4 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Aug 2016 to primary completion in Sep 2019, 37 months.
Results were first posted in Nov 2020, 1 year 2 months after primary completion.
Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 37 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Adalimumab